Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00500422 · ClinicalTrials.gov registry record · Phase 1
Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 134
- Enrollment target
NCT00500422: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00500422 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 134 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00500422, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 134 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest safe dose of the drug Velcade (bortezomib) that can be given together with gemcitabine and pegylated liposomal doxorubicin (Doxil) in the treatment of advanced cancer. The effect of this combination treatment on tumor growth will also be studied.
Interventions
- DRUG Gemcitabine
- DRUG Doxil
- DRUG Velcade
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 134 participants |
| Start Date | 2005-01 |
| Est. Completion | 2012-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00500422
The ClinicalTrials.gov registry entry for NCT00500422 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 134 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Gemcitabine is the first listed.
NCT00500422 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00500422 about?
NCT00500422 is a clinical study titled "Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients". The goal of this clinical research study is to find the highest safe dose of the drug Velcade (bortezomib) that can be given together with gemcitabine and pegylated liposomal doxorubicin (Doxil) in the treatment of advanced cancer. The effect of this combination treatment on tumor growth will also b...
What is the current status of trial NCT00500422?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 134 participants. The study started on 2005-01. Estimated completion is 2012-11.
What interventions are being tested in trial NCT00500422?
The interventions under investigation include: Gemcitabine (DRUG), Doxil (DRUG), Velcade (DRUG).
Who is sponsoring clinical trial NCT00500422?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.